Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Shares Issued (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Shares Issued for 12 consecutive years, with $362000.0 as the latest value for Q4 2025.

  • Quarterly Shares Issued fell 38.95% to $362000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 1223.74% year-over-year, with the annual reading at $2.4 million for FY2025, 26.32% up from the prior year.
  • Shares Issued for Q4 2025 was $362000.0 at Gyre Therapeutics, down from $1.3 million in the prior quarter.
  • The five-year high for Shares Issued was $49.3 million in Q1 2021, with the low at $275000.0 in Q2 2024.
  • Average Shares Issued over 3 years is $8.5 million, with a median of $593000.0 recorded in 2024.
  • Peak annual rise in Shares Issued hit 8263.64% in 2025, while the deepest fall reached 38.95% in 2025.
  • Over 3 years, Shares Issued stood at $49.3 million in 2021, then plummeted by 98.8% to $593000.0 in 2024, then crashed by 38.95% to $362000.0 in 2025.
  • According to Business Quant data, Shares Issued over the past three periods came in at $362000.0, $1.3 million, and $23.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.